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Abstract 
Astrocytes perform many homeostatic roles in the brain while supplying metabolites 
to neurons and mediating synaptic transmission. The current study explored a 
possible role of the Atrx gene in astrocytes. Hypomorphic mutations in this gene 
cause the ATR-X intellectual disability syndrome. Deletion of Atrx in the forebrain 
leads to an apparent increase in reactive astrocytes, potentially caused by the high 
level of neuroprogenitor cell death. To avoid such non cell-autonomous effects on 
astrocytes, we generated mice with inducible conditional inactivation of Atrx in 
astrocytes. Preliminary analysis two weeks following induction of Atrx gene deletion 
revealed variably lower expression of Connexin 30 (Gjb6), encoding a gap junction 
protein. Morphologically, ATRX-null astrocytes displayed larger domain coverage by 
peripheral astrocytic processes, suggesting altered functionality. This work provides 
key advances to our understanding of ATRX function in astrocytes and provides a 
unique mouse model for future investigations. 
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Chapter 1  
1 Introduction 
1.1 Astrocytes 
There are many different cell types in the brain, including neurons, and glia cells 
which include astrocytes, oligodendrocytes and microglia.  Research on brain 
development and function has historically been focused on neurons and 
oligodendrocytes. The astrocyte is only beginning to become an area of interest 
and appears to have importance in normal brain function. It was estimated that 
between 20 to 40% of all cells in mammalian brains are astrocytes (Herculano-
Houzel, 2014). The number of astrocytes does vary depending on species and 
area of the brain (Khakh and Sofroniew, 2015). Astrocytes are sparse in areas with 
numerous neuron cell bodies but are abundant in areas populated with axons and 
dendrites (Khakh and Sofroniew, 2015). Human astrocytes are up to 20x larger in 
volume and contact up to 10x more synapses compared to rodent astrocytes 
(Oberheim et al., 2009). Important synaptic proteins produced in astrocytes are 
more abundant in the human brain compared to chimpanzees and macaques 
(Caceres et al., 2007). These findings support an important role for astrocytes in 
the human brain.  
The functional diversity of astrocytes is still underappreciated, however two distinct 
types of astrocytes have been identified. Protoplasmic astrocytes are found in the 
gray matter and surround synapses (Sofroniew and Vinters, 2010). They have 
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many fine branches, called peripheral astrocytic processes (or PAPs) that connect 
to synapses, blood vessels, and other astrocytes, and account for approximately 
80% of the cell’s surface area (Rossi, 2015). Fibrous astrocytes are present in the 
white matter and have many long fiber-like processes that make contacts with 
axons (Sofroniew and Vinters, 2010). GFAP (glial fibrillary acidic protein) is used 
to label astrocytes, but this protein labels astrocyte subtypes differently (Rossi, 
2015). Fibrous astrocytes express higher levels of GFAP throughout their 
processes (Cahoy et al., 2008; Rossi, 2015) while GFAP expression is weaker in 
protoplasmic astrocytes and is mainly in the cell body and immediate large 
processes (Cahoy et al., 2008; Sofroniew and Vinters, 2010). The amount of GFAP 
present in astrocytes also varies in different brain regions. For example, 
hippocampal astrocytes express high levels whereas cortical astrocytes express 
low levels (Khakh and Sofroniew, 2015). GFAP is also upregulated in reactive 
astrogliosis (Sofroniew and Vinters, 2010), a topic that will be discussed further in 
the next section. There are many other differences between astrocytes, including 
morphology and density, depending on area of the murine brain (Emsley and 
Macklis, 2006; Khakh and Sofroniew, 2015).  
1.1.1 Functions of astrocytes in the CNS 
Astrocytes have long been regarded as support cells in the brain, as reviewed by 
Sofroniew and Vinters (2010) and Rossi (2015) (Figure 1). While they do perform  
10 
 
 
Figure 1. Astrocytes perform many essential functions at the synapse and 
the blood brain barrier. The astrocyte PAPs extend to make connections at the 
synapse and contact blood brain barrier with their endfeet. At the synapse, 
astrocytes release important neurotrophic factors during development to induce 
synapse formation. Lactate is released to neurons during periods of high neuronal 
activity and gliotransmitters are also released to help modulate synaptic function 
of neurons. Astrocytes also take up excess neurotransmitters present at the 
synapse. pH and ion homeostasis is maintained at the synapse through water and 
ion uptake by astrocytes. Astrocytes are the only cells that contact blood vessels 
in the brain and take up glucose and control water levels in the brain. Astrocytes 
can also release vasodilators to modulate blood flow based on neuronal activity 
and metabolic demand. 
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many vital functions to support neuronal homeostasis, astrocytes also have key 
roles in synaptic plasticity and the response to brain injury (Rossi, 2015; Sofroniew 
and Vinters, 2010).  Astrocytes are the only cell type in the brain to make contacts 
with the blood vessels and can secrete factors that mediate blood flow based on 
neural activity (Quaegebeur et al., 2011). They are also the site of glycogen 
storage in the brain, with the highest amount of glycogen accumulation in 
astrocytes in areas of high synaptic density (Belanger et al., 2011; Sofroniew and 
Vinters, 2010). Astrocytes also maintain fluid, ion, and pH homeostasis at the 
synapse (Rossi, 2015; Sofroniew and Vinters, 2010), contact blood vessels to 
allow for control of fluid homeostasis (Sofroniew and Vinters, 2010), and take up 
excess neurotransmitters from the synaptic space to prevent prolonged stimulation 
(Rossi, 2015; Sofroniew and Vinters, 2010). Astrocytes form a network with each 
other through gap junctions to allow for efficient communication and to deplete the 
molecules they take up and prevent accumulation of said molecules at the synapse 
and within a single astrocyte (Rossi, 2015; Sofroniew and Vinters, 2010). 
Astrocytes are also important in responding to brain injury, cell death, and 
inflammation as they are capable of forming glial borders, and possibly glial scars, 
to contain damage from an insult (Sofroniew and Vinters, 2010). Astrocytes 
responding to these events are called reactive astrocytes and their characteristics 
include: (1) upregulation of GFAP, as well as other genes, (2) hypertrophy of the 
cell body and processes, and (3) proliferation (if damage is significant) to 
reorganize the tissue and contain inflammation (Sofroniew and Vinters, 2010). This 
process is also referred to as astrogliosis. Depending on the severity of the brain 
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injury, a glial scar may form to act as a barrier around the injury to protect 
surrounding tissue from inflammation (Sofroniew and Vinters, 2010).  
1.1.2 Astrocyte development and maturation 
Astrocytes begin to appear just before birth at approximately embryonic day 18.5, 
or E18.5, and peak astrogliogenesis continues until postnatal day 7, or P7, in mice 
(Yang et al., 2013). Following the end of neurogenesis, radial glia progenitor cells 
switch from a neuronal to an astrocytic differentiation program (Anthony et al., 
2004; Yang et al., 2013). New astrocytes continue to divide while differentiating to 
produce clonal astrocytes locally (Garcia-Marques and Lopez-Mascaraque, 2013; 
Ge et al., 2012; Tsai et al., 2012), however, astrocytes are not fully mature until 3 
to 4 weeks after birth (Freeman, 2010; Yang et al., 2013). 
The morphological maturation of astrocytes that occurs postnatally involves the 
extension of PAPs. These processes are required to make contacts with other 
astrocytes, synapses and blood vessels (Yang et al., 2013). PAPs from one 
astrocyte can contact approximately 100,000 synapses in the rodent brain and up 
to 2,000,000 in the human as astrocyte size is drastically increased (Oberheim et 
al., 2006). These processes form between P14 and P26 (Yang et al., 2013) which 
is also the time of peak synaptogenesis (occurring between P14 and P21) 
(Freeman, 2010). PAPs often overlap between astrocytes during this time of 
intense outgrowth, but are eventually pruned so that astrocytes occupy specific 
and distinct domains by 4 weeks of age (Bushong et al., 2004). These astrocyte 
domains represent the area covered by PAPs. This morphological maturation is 
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followed, with brief overlap, by the induction of several astroglial genes. Glutamate 
transporter Slc1a2, gap junction proteins connexin 30 (Gjb6) and connexin 43 
(Gja1), and potassium channel Kir.1, for example, are all induced between P21 
and P28 (Yang et al., 2013). This timeline (Figure 2) suggests that mature 
astrocyte morphology is tightly associated with molecular maturation as the 
astroglial genes mentioned above are all membrane proteins present at PAPs and 
used at the synapse (Yang et al., 2013). 
1.1.3 The role of astrocytes at the synapse 
As astrocytes extend their processes they guide the migration of developing axons 
and neurons by forming molecular boundaries (Powell and Geller, 1999). 
Astrocytes also help refine synaptic processes by taking part in synaptic pruning 
(Stevens et al., 2007). Stevens et al. reported that C1q, an initiating protein in the 
complement cascade (part of the innate immune system response) is upregulated 
in postnatal neurons in the presence of immature astrocytes. C1q was later 
determined to be induced by TGF-β, an astrocyte-secreted factor that initiates the 
complement cascade in neurons, leading to synaptic pruning in the developing 
visual system (Bialas and Stevens, 2013).   
Astrocytes are also extremely important in synaptogenesis. A pioneering study 
provided evidence that synapse formation was limited without the presence of glial 
cells (Ullian et al., 2001). The authors demonstrated that neurons cultured in the 
absence of astrocytes, or astrocyte-conditioned media, formed very few synapses 
and those that did form were functionally immature (Ullian et al., 2001). Through 
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Figure 2. Timeline of astrocyte development in the mouse. Embryonic day 0 
(E0) represents conception and peak astrogliogenesis, or astrocyte production, 
occurs shortly before birth at E18.5 and continues to approximately a week after 
birth (P7). The astrocytes produced are immature and do not begin to extend PAPs 
and form networks with each other and synapses until two weeks after birth (P14). 
This morphological maturation of astrocytes overlaps with peak synapse formation 
between neurons. Molecular maturation through expression of astroglial genes 
also overlaps with the end of the morphological maturation period, beginning at 3 
weeks after birth (P21).   
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the use of electron microscopy and immunofluorescence directed at detecting 
synaptic proteins and astrocytic markers, they demonstrated that synapse 
formation corresponds with the appearance of astrocytes in the mouse brain 
(Ullian et al., 2001).  
Many astrocyte-secreted molecules were subsequently identified as important 
signals for synapse formation and stability. Thrombospondins are released from 
astrocytes and promote synaptogenesis (Christopherson et al., 2005). These 
molecules induce the structural formation of new synapses that are functionally 
immature and cannot produce an action potential (Christopherson et al., 2005). 
Another astrocyte signaling factor, Hevin, induces excitatory synapse formation 
while its inhibitor secreted protein, acidic, cysteine-rich (SPARC) prevents 
synapse formation (Kucukdereli et al., 2011). SPARC prevents excessive 
excitation of synapses by controlling the level of alpha-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid receptors (AMPARs) at the synapse (Jones et al., 
2011). Loss of SPARC in mice results in accumulated AMPAR at synapses and 
impaired synaptic plasticity (Jones et al., 2011). SPARC inhibits integrin 
complexes associated with AMPARs (Jones et al., 2011). Therefore in the absence 
of SPARC, sustained stability of the AMPAR at synapses is achieved resulting in 
increased excitatory synapse function and reduced synaptic plasticity (Jones et al., 
2011). Astrocyte-derived cholesterol is also required during synaptogenesis as 
retinal ganglion cells (RGCs) were unable to form immature synapses without 
cholesterol supplied by astrocytes (Mauch et al., 2001). The RGCs were able to 
produce enough cholesterol to differentiate and extend dendrites and axons but 
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large amounts of cholesterol were required to form functional synapses (Mauch et 
al., 2001).  
After formation of synapses there are signals that lead to synaptic maturation and 
reinforce synaptic strength. Allen et al. identified astrocyte-secreted glypicans 4 
and 6 as molecules that are able to induce functionally mature synapses (Allen et 
al., 2012). Glypicans increase the surface level and clustering of a subunit of the 
AMPAR (Allen et al., 2012). The authors also demonstrated that glypican 4-
deficient mice had defective synapse formation and reduced amplitude of 
excitatory synaptic currents in the hippocampus (Allen et al., 2012). Extracellular 
matrix components have also been implicated in reinforcing synaptic strength by 
stabilizing the AMPAR at synapses and preventing mobility (Frischknecht et al., 
2009). In another study, hippocampal neurons were cultured on an astrocyte 
feeder layer resulting in the formation of many synapses (Pyka et al., 2011). 
However, with the addition of enzymes that digest certain astrocyte-secreted 
extracellular matrix factors these synapses became weaker and also resulted in 
an accumulation of immature synapses (Pyka et al., 2011).  
Astrocytes are important for synapse development and plasticity of neurons, but 
what is their role at a functional synapse? As mentioned previously, astrocytes 
possess glutamate transporters required for proper glutamate clearance at the 
synapse to prevent excitotoxicity and neurodegeneration (Rossi, 2015; Rothstein 
et al., 1996; Sofroniew and Vinters, 2010). Astrocytes also release various 
“gliotransmitters”, in response to synaptic activity (reviewed in (Araque et al., 
2014). There are in fact many gliotransmitters that are released in response to 
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Ca2+ elevation in astrocytes, including astrocytic glutamate, ATP, D-serine, and 
TNFα (Araque et al., 2014).  Astrocytic glutamate has been implicated in 
modulating the frequency of excitatory and inhibitory postsynaptic potentials and 
of basal synaptic transmission in the hippocampus. It is also able to modulate long 
term depression in the cortex (Araque et al., 2014). ATP has been implicated in 
modulation of long term potentiation, basal synaptic depression, and depression 
of evoked excitatory postsynaptic potentials in the hippocampus and regulation of 
basal synaptic transmission in the cortex (Araque et al., 2014). D-serine has been 
strongly implicated in long term potentiation in the hippocampus and both long term 
potentiation and depression in the cortex. Finally TNFα has been associated with 
insertion of AMPARs to strengthen synapses (Araque et al., 2014). Although these 
gliotransmitters have been implicated in neuromodulation, many mechanistic 
questions remain unanswered such as how certain astrocyte receptors are 
differentially activated to cause Ca2+ elevation and how this leads to the release of 
different gliotransmitters (Araque et al., 2014). The mechanism behind the release 
of each gliotransmitter requires more attention to fully understand how astrocytes 
function at the synapse. 
The plasticity of astrocyte morphology has been implicated in promoting excitatory 
synapse stability (Bernardinelli et al., 2014). In response to synaptic activity, 
specifically activation of metabotropic glutamate receptors (mGluRs) by neuronal 
glutamate resulting intracellular Ca2+ signaling, PAPs undergo structural 
remodeling to enhance active synapse coverage and synapse stability 
(Bernardinelli et al., 2014). The authors explored this further by activating single-
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synapses through photoactivation to demonstrate that this PAP mobility is synapse 
specific and therefore astrocytes contacting many synapses can respond to each 
individually (Bernardinelli et al., 2014). This mobility of PAPs and their ability to 
respond to and strengthen individual synapses implies that astrocytes may be 
involved in long term potentiation and ultimately learning and memory 
(Bernardinelli et al., 2014). 
1.1.4 Astrocyte involvement in the pathology of 
neurodevelopmental disorders 
Neurodevelopmental disorders are characterized through a set of similar 
symptoms such as cognitive impairments, autistic features, epilepsy and motor 
abnormalities. The research conducted on these disorders has focused mostly on 
neuronal dysfunction; however, recent studies have emerged describing a role for 
astrocytes as a contributor to pathology of these disorders. Autism spectrum 
disorder is a set of neurodevelopmental disorders without an identified single 
etiology, because it is most likely caused by both genetic and environmental 
factors (Fakhoury, 2015). Autistic patients exhibit reduced language and social 
skills, repetitive behaviours and with some secondary symptoms such as 
aggression and anxiety (Fakhoury, 2015). Postmortem brain samples from autistic 
patients revealed astrogliosis as indicated by elevated GFAP protein levels 
(Laurence and Fatemi, 2005). The mRNA levels of two astrocyte-specific 
glutamate transporters were also increased in patient samples, mainly from the 
cerebellum (Purcell et al., 2001). In another study protein levels of water channel 
gene aquaporin 4 (Aqp4) were decreased in the cerebellum and gap junction 
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protein Gja1 was increased in the superior frontal cortex of autistic patients (Fatemi 
et al., 2008). Gain-of-function mutations in another key astroglial gene, potassium 
channel Kir4.1, have been found in autistic patients with seizures indicating a 
possible causative mechanism for altered neuronal excitability (Sicca et al., 2011). 
These findings indicate a pathological role for astrocytes in patients with autism. 
Many other neurodevelopmental disorders contain both autistic features and 
epilepsy, including Fragile X syndrome. 
Fragile X syndrome is caused by the transcriptional silencing of fragile X mental 
retardation protein (FMRP), a translational repressor, due to hypermethylation of 
a large repeat present in the FMR1 gene locus on the X chromosome (Verkerk et 
al., 1991). Fragile X syndrome is the most common form of inherited intellectual 
disability and affected males display intellectual disability, seizures, motor 
abnormalities and autistic features, such as the inability to communicate effectively 
(Gallagher and Hallahan, 2012; Kidd et al., 2014). Astrocytes lacking FMRP were 
co-cultured with wildtype neurons to determine if proper neuronal growth could be 
supported by fmr1-/- astrocytes (Jacobs and Doering, 2010). These neurons 
displayed abnormal dendrite morphology and decreased levels of presynaptic and 
postsynaptic protein aggregates (Jacobs and Doering, 2010). This phenotype was 
absent when neurons were cultured with normal astrocytes, indicating fmr1-/- 
astrocytes cannot support proper neuronal growth and synapse formation (Jacobs 
and Doering, 2010). Another study determined that astroglial glutamate transporter 
Slc1a2 protein levels were reduced in the fmr1-/- mouse cortex and this resulted in 
reduced glutamate uptake (Higashimori et al., 2013). The authors determined that 
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fmr1-/- astrocytes expressed similar levels of Slc1a2 when compared to wildtype 
astrocytes but could not upregulate Slc1a2 expression in response to neurons 
(Higashimori et al., 2013). This was a result of loss of mGluR5 receptor, which was 
regulated by FMRP (Higashimori et al., 2013). The above evidence therefore 
indicates astrocytes as important contributors to Fragile X syndrome pathologies.  
Rett syndrome is caused by loss of function mutations in an X-linked gene called 
MeCp2 (Amir et al., 1999). The methyl CpG binding protein 2 (MeCP2) protein is 
a chromosomal protein that preferentially binds 5-methyl cytosine in CpG 
dinucleotides (Lewis et al., 1992). This protein functions as a transcriptional 
repressor by changing chromatin structure, making genes more or less accessible 
(Nan et al., 1998). Baby girls affected by this disorder initially appear normal but 
exhibit developmental and cognitive regression at 12 to 18 months of age along 
with loss of verbal skill and motor abnormalities (Dolce et al., 2013). Recent 
literature describes a cell non-autonomous role for astrocytes in Rett syndrome 
pathology. Ballas et al. found that MeCP2 was lost in both neurons and astrocytes 
in Rett syndrome brains (Ballas et al., 2009). They also determined that wildtype 
neurons cultured with mutant astrocytes from a Rett syndrome mouse model, or 
treated with mutant astrocyte-derived media, resulted in abnormal dendrite 
morphology (Ballas et al., 2009). Astrocytes lacking MeCP2 grew significantly 
slower than wildtype astrocytes and MeCP2 levels in heterozygous female 
(MeCP2-/+) cultured astrocytes decreased when left in culture for longer than 2 
weeks (Maezawa et al., 2009). MeCP2 transcript levels remained the same in 
these cells and inhibition of astrocyte gap junctions prevented the spread of 
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MeCP2 deficiency through astrocytes (Maezawa et al., 2009). MeCP2-null 
astrocytes have altered expression of several astroglial genes and impaired 
glutamate clearance in vitro (Okabe et al., 2012). An exciting rescue study re-
expressed MeCP2 only in astrocytes in MeCP2-deficient mice and several 
symptoms were rescued, such as restored respiratory abnormalities, improved 
locomotion and prolonged life span (Lioy et al., 2011).  The discovery that 
astrocytes are defective in the brains of Rett syndrome girls confirms that astrocyte 
biology must be investigated to fully understand the underlying causes of 
neurodevelopmental disorders.  
1.1.5 Alpha thalassemia mental retardation X-linked syndrome 
Alpha thalassemia mental retardation, X-linked syndrome is caused by mutations 
in the X-linked ATRX gene (Gibbons et al., 1995), which encodes a chromatin-
remodeling protein. This syndrome affects males due to its X-linked nature and 
has the following symptoms: moderate to severe intellectual disability, 
characteristic facial abnormalities, alpha thalassemia blood disorder, skeletal 
abnormalities, microcephaly, seizures, genital abnormalities (Gibbons, 2006) and 
myelination defects (Wada et al., 2013). ATR-X syndrome has many overlapping  
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Table 1. Overlapping symptoms of three neurodevelopmental disorders 
Feature of disorder Fragile X 
Syndrome 
Rett 
Syndrome 
ATR-X 
syndrome 
Cognitive Impairment    
Autistic features    
Epilepsy     
Motor abnormalities    
Abnormal expression of a 
chromatin remodeling protein  
X   
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features with Rett Syndrome and Fragile X syndrome (Table 1). Furthermore 
MeCP2 interacts with ATRX, and this interaction is important for ATRX recruitment 
to sites of heterochromatin (Nan et al., 2007). These observations suggest an 
overlap at both the phenotypic and molecular level between these 
neurodevelopmental disorders. 
1.2 ATRX is a key regulator of chromatin structure 
1.2.1 Gene location and protein structure 
The ATRX gene is located on the X chromosome at Xq13.3 (Gibbons et al., 1995) 
and undergoes X inactivation (Gibbons et al., 1992). This gene contains 36 exons 
and is 300 kb long, giving rise to a 280 kDa protein (Picketts et al., 1996) that is 
ubiquitously expressed in humans and mice (Gecz et al., 1994; Stayton et al., 
1994). A 200 kDa truncated form of ATRX, ATRXt, was reported (Berube et al., 
2000; McDowell et al., 1999) and shown to result from alternative splicing of the 
gene (Garrick et al., 2004). ATRX has two highly conserved domains (Picketts et 
al., 1998): the N-terminal ATRX-DNMT3-DNMT3L (ADD) domain that is 
homologous to the DNA methyltransferase family (Aapola et al., 2000) and the C-
terminal Swi/Snf helicase domain that contains an ATPase/helicase motif (Picketts 
et al., 1996) (Figure 3).  
The ADD domain recognizes modified histone tails, specifically H3K9me3 in 
combination with unmethylated H3K4 (Dhayalan et al., 2011; Eustermann et al., 
2011; Iwase et al., 2011). The switch/sucrose-nonfermenting (SWI/SNF) domain 
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Figure 3. Schematic of ATRX protein. The conserved domains ADD, Swi/Snf 
and PML body (promyelocytic leukemia body) targeting domains are indicated by 
the blue regions while protein interaction sites are indicated by purple regions. The 
ATRXt premature stop codon that gives rise to the truncated form of ATRX is 
represented by the arrow. The seven highly conserved collinear helicase domains 
in the Swi/Snf domain are represented by the vertical black lines in the conserved 
domain region. The red line indicates the approximate location of the loxP sites 
inserted in the Atrx floxed mice used in this work. Figure adapted from review by 
Nathalie Bérubé (Berube, 2011). 
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closely resembles the Rad54 family of proteins (Picketts et al., 1998) and is 
characterized by seven highly conserved collinear helicase domains (Picketts et 
al., 1998) that confer the ATPase and chromatin-remodeling activities of ATRX 
(Tang et al., 2004). ATRX associates with many proteins such as heterochromatin-
associated protein 1 alpha (HP1α) (Berube et al., 2000; McDowell et al., 1999), 
death-associated protein 6 (Daxx) (Tang et al., 2004; Xue et al., 2003), and methyl-
CpG-binding protein (MeCP2) (Nan et al., 2007) (Figure 3). A proportion of ATRX 
and Daxx colocalize to promyelocytic leukemia nuclear bodies (PML bodies) in the 
nucleus (Xue et al., 2003). The conserved domains of the ATRX protein and the 
aforementioned protein-protein interactions are vital for its diverse cellular 
functions. The majority of disease-causing mutations map within the ADD and 
SWI/SNF domains of ATRX and result in reduced expression or activity of the 
protein (Gibbons et al., 1995; Picketts et al., 1996).  
1.2.2 ATRX’s diverse functions in the cell and at chromatin 
ATRX is an exclusively nuclear protein and associates with pericentromeric 
heterochromatin throughout all stages of the cell cycle (Berube et al., 2000; 
McDowell et al., 1999). ATRX also associates with highly repetitive sequences in 
both telomeres and euchromatin (Law et al., 2010). ATRX interacts with 
heterochromatin through its N-terminal domain (McDowell et al., 1999), particularly 
using its ADD domain to bind H3K9me3 (Dhayalan et al., 2011). ATRX is also 
phosphorylated in a cell cycle dependent manner (Berube et al., 2000). 
26 
 
ATRX and its binding partner Daxx localize to pericentric heterochromatin DNA 
repeats and telomeres and control transcription of these repeats by integrating 
histone variant H3.3 into nucleosomes (Drane et al., 2010; Goldberg et al., 2010). 
H3.3 is a replication independent histone variant that is associated with open and 
active chromatin (Loyola et al., 2006). ATRX binds Daxx/H3.3 to target repetitive 
sequences to deposit H3.3 (Drane et al., 2010). Loss of ATRX in the neonatal 
forebrain resulted in altered transcript levels of a subset of genes, including 
ancestral pseudoautosomal genes and a network of imprinted genes (Kernohan et 
al., 2010; Levy et al., 2008). The method of imprinted gene regulation was further 
investigated, leading to the model in which ATRX and MeCP2 position 
nucleosomes around CCCTC-binding factor (CTCF) binding sites (Kernohan et al., 
2014). CTCF is involved in chromatin looping to separate or bring together 
enhancers and/or repressor and regulate the expression of nearby genes (Ong 
and Corces, 2014). Through regulation of chromatin looping, ATRX and MeCP2 
can coordinate gene expression of selected imprinted genes (Kernohan et al., 
2014). Another mechanism for ATRX regulation of gene expression in a subset of 
genes, including autism susceptibility gene Neuroligin 4, is the incorporation of 
H3.3 at G-rich regions of the gene body (Levy et al., 2015). ATRX was found to 
interact with G-quadraplexes, a secondary structure that forms in regions of DNA 
rich in guanine, in vitro (Law et al., 2010) and ATRX-null neuroprogenitors treated 
with a drug that stabilizes G-quadraplex formation had increased DNA damage 
(Watson et al., 2013). Levy et al. determined that ATRX deficiency in the mouse 
forebrain resulted in decreased H3.3 incorporation and stalled RNA polymerase II 
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at G-rich intragenic sites (Levy et al., 2015). These findings suggest that ATRX 
helps resolve G-quadraplex formation through H3.3 deposition at these regions to 
allow transcriptional elongation (Levy et al., 2015).  
Loss of ATRX also results in replication and mitotic abnormalities. ATRX depletion 
in human HeLa cells led to many mitotic defects including: prolonged 
prometaphase to metaphase transition, abnormal sister chromatid congression 
and reduced sister chromatid cohesion at the metaphase plate, chromosome 
decondensation and overall lengthening of mitosis (Ritchie et al., 2008). 
Micronuclei, pyknotic nuclei and misaligned chromosomes were also identified in 
vivo in embryonic mouse brain sections (Ritchie et al., 2008). Interestingly, ATRX 
depletion in mouse myoblasts also led to mitotic defects, genomic instability, 
telomere defects and p53 accumulation (Huh et al., 2012). Atrx deletion resulted 
in increased sensitivity to replication stress-inducing agents with increased double 
strand breaks, increased S phase population, and accumulated DNA damage at 
telomeres (Leung et al., 2013; Watson et al., 2013). Proper replication restart after 
DNA damage, prevention of replication fork stalling and progression through S-
phase also require ATRX (Clynes et al., 2014; Leung et al., 2013).  ATRX is 
important for proper meiotic spindle organization and chromosome alignment in 
meiosis in the mouse oocyte (De La Fuente et al., 2004).  
1.2.3 ATRX and neuronal development 
ATRX is important in neurons during development, as exhibited by mouse models 
with both loss and overexpression of ATRX. One model using transgenic mice that 
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overexpress ATRX exhibited embryonic lethality and those pups that did survive 
exhibited craniofacial abnormalities and disorganization of the proliferative 
neuroepithelium (Berube et al., 2002). Berube et al. created a mouse model that 
used Cre recombinase mediated deletion of Atrx by flanking exon 18 with loxP 
sites under the control of the Foxg1 promoter (Berube et al., 2005). Foxg1 
expression is confined to the forebrain in mice and expression begins at E8.5, 
causing conditional deletion of ATRX in these cells (Hebert and McConnell, 2000). 
Male mice lacking ATRX in the forebrain were smaller in length and weight than 
their wildtype counterparts and exhibited cortical and hippocampal size reduction 
(Berube et al., 2005). These regions were hypocellular due to increased apoptosis 
and not a defect in proliferation (Berube et al., 2005). This cell death in the ATRX-
null forebrain was determined to be p53-mediated as deletion of both ATRX and 
p53 rescued cell death in the brain (Seah et al., 2008).  
Further investigation of these mice with conditional inactivation of ATRX 
specifically in the embryonic forebrain revealed increased DNA damage through 
γH2AX (a marker for double-stranded breaks) immunostaining, and these cells 
also had elevated levels of cleaved caspase 3, an apoptosis marker (Watson et 
al., 2013). These mice also exhibited systemic effects, such as reduced life span, 
heart enlargement, decreased bone mineral density and reduced circulating levels 
of thyroxine and IGF-1, due to ATRX being deleted in the anterior pituitary as well 
as the forebrain (Watson et al., 2013). Another study using the same mouse model 
found an increase in cell-cycle exit in early to mid-neurogenesis and a depletion in 
progenitor cells leading to disproportionate layering of neurons in the cortex 
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(Ritchie et al., 2014). ATRX was also required for correct timing of neuroprogenitor 
differentiation (Ritchie et al., 2014). These findings ascertained the importance of 
ATRX in neurons. However, our understanding of ATRX function in other cell types 
of the central nervous system, such as astrocytes, is severely lacking. As 
previously mentioned, MeCP2-null astrocytes display growth defects, and co-
culture with wild-type neurons demonstrated that MeCP2-deficient astrocytes are 
unable to support dendritic growth and maturation (Ballas et al., 2009; Maezawa 
et al., 2009). Given that MeCP2 deficient astrocytes fail to recruit ATRX to 
chromatin, we predict that ATRX-null astrocytes will display similar defects.  This 
question can be addressed by developing a model of ATRX inactivation specifically 
in astrocytes and this was the main goal of the present thesis. 
1.3 Hypothesis and Summary of Findings  
The role of astrocytes in the pathology of neurodevelopmental disorders is an 
emerging focus of research. With cell non-autonomous effects on neurons 
demonstrated in similar neurodevelopmental disorders, the role for astrocytes in 
ATR-X syndrome pathology requires investigation. I hypothesize that ATRX is 
important for proper astrocyte development and function and that creation of a 
novel mouse model will allow the study of ATRX in astrocytes.  
The effect of Atrx deletion in astrocytes was assessed in a mouse model where 
ATRX is conditionally deleted in the forebrain (Berube et al., 2005). The protein 
levels of ALDH1L1, an astrocyte-specific marker, were decreased in the cKO 
males but this decrease was variable between 3 control and cKO pairs and did not 
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reach significance. Cell counts were performed to determine whether this decrease 
in ALDH1L1 is due to decreased protein expression per cell or a decrease in 
astrocyte population. There was a slight, but non-significant decrease in Aldh1l1 
positive nuclei in the cKO. Variability in astrocyte number between control and cKO 
pairs was observed. Analysis of a previously performed microarray revealed 
altered expression of astrocyte-enriched genes and gene ontology analysis 
determined enriched, altered astrocyte functional pathways in cKO males when 
compared to controls. 
Mice with inducible and conditional inactivation of Atrx in astrocytes were created.  
Atrx deletion in astrocytes was validated through hippocampal cell counts 
revealing GFAP positive cells lacking ATRX at P26. Immunofluorescence staining 
for ATRX, DAPI and GFAP in the cerebellum revealed many nuclei lacking ATRX 
staining. Measurement of Atrx mRNA levels in the hippocampus and cortex of 
inducible KOs revealed no significant difference when compared to controls. To 
further investigate the induction of Cre recombinase by tamoxifen, a double 
fluorescent reporter allele was utilized. This allele expresses GFP in response to 
Cre recombinase activity, and therefore in astrocytes in response to tamoxifen 
treatment in this model. GFP expression in the cortex and hippocampus was only 
present in males carrying the inducible Cre recombinase allele in response to 
tamoxifen.  
Assessment of astrocyte domain size and morphology was accomplished through 
use of the previously mentioned double fluorescent reporter allele. The inducible 
KO demonstrated larger astrocyte domains and an increased amount of GFP 
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domain induction by tamoxifen. This indicated that more astrocytes are responding 
to tamoxifen-mediated recombination. The larger domains observed may be due 
to larger astrocyte domains or to increased overlap between separate astrocyte 
domains. qRT-PCR of astroglial genes demonstrated a decrease in connexin 30, 
a component of astrocyte gap junctions, expression. Although this decrease did 
not reach significance, additional biological replicates should be analyzed to 
investigate the possible altered levels in the inducible KO.  Decreased expression 
of Connexin 30 could lead to communication defects between astrocytes as it is 
one of only two gap junction proteins connecting the astroglial network. 
2 Materials and Methods 
2.1 Animal Husbandry and Genotyping 
Several mouse lines were used throughout the following studies and these are 
summarized in Table 2. AtrxloxP(or Atrxf/f) mice containing loxP sites flanking intron 
18 of Atrx (Figure 4) were kindly provided by D. Higgs (Weatherall Institute of 
Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom). 
Recombination of these loxP sites result in the deletion of exon 18, which is 
equivalent to a null mutation of Atrx (Figure 4) (Berube et al., 2005).  
First, conditional deletion of Atrx in the mouse forebrain was achieved by crossing 
Atrxf/WT female mice (129Sv background) with heterozygous FoxG1-Cre 
recombinase knock-in males (129Sv/FVBN background). The FoxG1-Cre 
recombinase mice were originally obtained from S. McConnell (Stanford 
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University, Stanford, California, USA). Cre recombinase driven by the FoxG1 
promoter directs recombination and silencing of Atrx in cells with the loxP allele in 
the mouse forebrain beginning at embryonic day 8.5 (E8.5, (Hebert and 
McConnell, 2000)). Male offspring of this cross resulted in two genotypes used in 
this study: Atrxf/YFoxG1-Cre+, who lack ATRX in the forebrain, and AtrxWT/YFoxG1-
Cre+, who will still express ATRX despite also expressing Cre recombinase but 
lack the loxP-flanked Atrx allele. 
Secondly, to achieve spatial and temporal deletion of Atrx in astrocytes, Atrxf/WT 
female mice were crossed to males carrying the transgenic Glast-CreERT 
recombinase allele (Mori et al., 2006; Slezak et al., 2007) (Jackson Laboratory, 
C57BL/6 background). Glast-CreERT allele expresses Cre recombinase in 
response to tamoxifen treatment in retinal muller glia, Bergmann glia in the 
cerebellum, astrocytes, and neural progenitors in the dentate gyrus (Mori et al., 
2006; Slezak et al., 2007). The Cre recombinase enzyme is fused to the estrogen 
receptor and stimulation with tamoxifen leads to translocation of the enzyme into 
the nucleus where it can induce recombination. Atrxf/YGlast-CreERT mice will delete 
Atrx in response to tamoxifen while the control males, AtrxWT/YGlast-CreERT, will 
have active Cre recombinase with the addition of tamoxifen but will still express 
the wildtype Atrx allele.  
Finally, females heterozygous for the Atrx floxed allele and carrying a knock-in 
double reporter allele, mT/mGWT/+ (129Sv background), were also crossed with 
Glast-CreERT males. This double reporter allele, driven by the chicken β-actin 
promoter, causes ubiquitous expression of tdTomato (mT) (Muzumdar et al., 
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2007). The coding sequence of membrane-targeted tdTomato is flanked by loxP 
sites (Muzumdar et al., 2007). Upon Cre-activation, the tdTomato sequence is 
excised and membrane-targeted enhanced green fluorescent protein (GFP) is 
then expressed (mG) (Muzumdar et al., 2007) (Figure 5). This means that cells 
expressing Cre-recombinase driven by the Glast promoter will switch from 
tdTomato fluorescence to GFP fluorescence upon tamoxifen administration. 
Atrxf/YGlast-CreERTmT/mGWT/+ astrocytes will lack ATRX and exhibit GFP 
fluorescence in response to tamoxifen administration. AtrxWT/YGlast-CreERTmT/mG 
WT/+ astrocytes will still express ATRX but will also express GFP due to the 
activation of Cre recombinase by tamoxifen. Mice lacking the Glast-CreERT allele 
but carrying the mT/mG allele will only express tdTomato fluorescence.  
For genotyping, tail or ear notch samples from mice were digested and genomic 
DNA was extracted using DirectPCR and proteinase K (Thermo Scientific). DNA 
from these samples was then genotyped by PCR using primer sets for Atrx (17F, 
18R and neoR), Glast-CreERT (GlastF, GlastR), mT/mG (mT/mG+ F, mT/mG+ R), 
and Sry (SryF and SryR), as listed in Table 3. Placement of loxP sites in the Atrx 
gene is indicated by Figure 4, which also corresponds to primers used to genotype 
the Atrx gene in Table 3.  
2.2 Tamoxifen Preparation and Injection 
Tamoxifen (≥99%, Sigma) was diluted to 10 mg/mL for tamoxifen injections. The 
appropriate amount of the drug was measured and dissolved in ethanol (95%) at  
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Table 2. Summary of mouse genotypes used within this thesis, grouping 
control and knockout pairs compared by colour. 
Genotype Description Referred to as 
AtrxWT/YFoxG1-Cre+ Cre recombinase positive 
control 
Control 
Atrxf/YFoxG1-Cre+, Conditional inactivation in 
forebrain cells 
cKO 
AtrxWT/YGlast-CreERT Inducible Cre recombinase 
positive control 
Control 
Atrxf/YGlast-CreERT Inducible inactivation in 
astrocytes 
Inducible KO 
AtrxWT/YGlast-
CreERTmT/mG WT/+ 
Fluorescent Cre recombinase 
positive control 
Fluorescent 
Control 
AtrxWT/YGlast-
CreERTmT/mG WT/+ 
Fluorescent inducible 
knockout in astrocytes 
Fluorescent 
Inducible KO 
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Figure 4. LoxP site placement in Atrx gene. Blocks and corresponding numbers 
represent respective exons in the Atrx gene. The top line indicates the wildtype 
Atrx allele (AtrxWT). The middle line shows the insertion of loxP sequences flanking 
exon 18 along with a neo marker (Atrxf). The bottom line demonstrates the 
recombination of Atrx upon Cre recombinase activation in which exon 18 and the 
neo cassette have been removed (AtrxΔ18Δneo). 
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Figure 5. Schematic representation of the mT/mG fluorescent reporter allele. 
The mT/mG allele under the control of the chicken β-actin promoter with flanking 
loxP sites around the tdTomato allele (mT) (represented by arrows). After Cre 
recombinase is activated, the tdTomato sequence is excised allowing expression 
of membrane-targeted enhanced green fluorescent protein (GFP or mG). The 
arrow indicates direction of transcription and pA denotes polyadenylation sites 
present. Adapted from Muzumdar et al. (2007). 
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Table 3. List of Primers used for genotyping  
Primer Name Sequence (5’ to 3’) 
Atrx 17F  AGAACCGTTAGTGCAGGTTCA 
Atrx 18R TGAACCTGGGGACTTCTTTG 
Atrx neoR CCACCATGATATTCGGCAAG 
Sry F GCAGGTGGAAAAGCCTTACA 
Sry R AAGCTTTGCTGGTTTTTGGA 
Glast F ACAATCTGGCCTGCTACCAAAGC 
Glast R CCAGTGAAACAGCATTGGTGTC 
mT/mG+ F  CTCTGCTGCCTCCTGGCTTCT 
mT/mG+ R TCA ATG GGCGGGGGTCGTT 
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10% of the final volume. This solution was heated at 65°C until the tamoxifen was 
completely dissolved. Ninety percent of the total volume of corn oil (Sigma) was 
added to the ethanol-tamoxifen solution to achieve the desired concentration of 10 
mg/mL. 
Two injection protocols were used in this study. Adult males (3 months) were 
injected intraperitoneally with 2 mg of tamoxifen (200 μL of 10 mg/mL) daily for 5 
days. These control and inducible knockout males were then sacrificed 1 week 
post-final injection for experimental analysis. Males were also injected at an earlier 
time point. Intraperitoneal injections of 1 mg of tamoxifen (100 μL of 10 mg/mL) 
began at postnatal day 10 (P10) and continued daily for 3 days until P12. Control 
and inducible knockout males were then sacrificed 2 weeks post-final injection at 
P26. 
2.3 Western Blot Analysis 
Tissue was mixed with cold RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% 
NP-40, 0.5% deoxycholic acid, 0.1% SDS, 0.2 mM PMSF, 0.5 mM NaF, 0.1 mM 
Na3VO4) (3 mL per gram of tissue) and homogenized and incubated on ice for 30 
minutes. The samples were then centrifuged at 4°C at 15800 g for 30 minutes and 
the supernatant transferred to a new, cold 1.5 mL Eppendorf tube, discarding the 
cell pellet. The protein concentration was then measured using a Bradford assay 
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(BioRad). Protein extracts were stored at -80°C. The samples were thawed when 
required and denatured at 90°C for 10 minutes.  
Polyacrylamide gels, including a separating gel (10%) and a stacking gel (4%) 
were generated and 25 μL of each sample in 1x loading buffer were loaded into 
the gel along with 8 μL of protein ladder (BioRad). Gels were run at 90V for 30 
minutes, then 125-130 V for 2 hours in 1x running buffer. Once adequate protein 
separation was achieved, the gels were transferred to nitrocellulose membranes 
(BioTraceTM, Pall Life Sciences) and run at 75 V for 2 hours in 1x transfer buffer. 
The transferred nitrocellulose membranes were blocked for 1 hour with 5%-milk-
TBST. Primary antibody diluted in 5%-milk-TBST was added and the membrane 
was incubated at 4 °C overnight. Membranes were then washed with 1x TBST and 
secondary antibody diluted in 5%-milk-TBST was added. The membrane was 
incubated in the secondary antibody for 1 hour and then washed with 1x TBST. 
ECL (enhanced chemiluminescence) solution was then added to membrane for 
approximately one minute. The membranes were then imaged using the BioRad 
ChemiDoc MP imaging system. Antibodies and respective dilutions are displayed 
in Table 5. An unpaired t-test was performed to reveal significance between control 
and cKO mice (p<0.05). 
2.4 Quantitative Real Time PCR (qRT-PCR) 
The brain samples were extracted at various timepoints (P26 or 3 months) 
depending on the experiment. The cortex and hippocampus were isolated and 
stored at -80°C. RNA was then extracted from thawed samples using the RNeasy® 
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Mini or Micro Kit (Qiagen).  The extracted RNA was then reverse transcribed into 
cDNA by the following protocol: RNA (1 μg), DEPC-H2O and random primers were 
heated for 10 minutes at 65°C, and then incubated on ice for two minutes. Next, 
5X first strand buffer, 100 mM DTT, 25 nM dNTPs, Superscript Reverse 
Transcriptase, RNA guard and more DEPC-H2O were added to the reaction 
mixture. Control reactions lacking reverse transcriptase were performed to ensure 
reagents were not contaminated. The reaction mixture was then incubated first for 
10 minutes at 30°C and then for 45 minutes at 42°C. The resulting cDNA was 
quantified and stored at -20°C.  
qRT-PCR was performed on the cDNA prepared from extracted RNA. Primers 
used are listed in Table 4. cDNA was mixed with primers, H2O and iQTM SYBR® 
Green mastermix (BioRad) and run through the following conditions on a Chromo-
4 thermocycler to amplify transcripts of interest: 30-35 cycles of 95°C for 10 
seconds, 55°C for 20 seconds and 72°C for 30 seconds. A final melting curve was 
generated in increments of 1°C per plate read. Gene expression analysis was 
performed using Opticon Monitor 3 and GeneX (Biorad) software. Analysis of each 
cDNA sample was performed in duplicate for each primer set and gene expression 
was normalized to Gapdh expression levels. An unpaired t-test was performed to 
reveal significance between control and inducible KO mice (p<0.05). 20 μL of qRT-
PCR product was run on a 1.5% agarose gel by electrophoresis to ensure band 
size of amplified cDNA matched the transcript of interest.  
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2.5 Immunofluorescence and Cell Counts 
Brains were dissected and perfused with 4% PFA at varying ages (P7, P20, P26, 
3 months) and were embedded in OCT (optimal cutting temperature) medium and 
snap frozen in liquid nitrogen. The samples were then stored at -80°C until 
cryosectioned sagittally or coronally at a thickness of 8 μM. Sections used for 
immunofluorescence were thawed at room temperature for 1 hour. Matched slides 
between pairs (control and knockout) were then rehydrated in 1x PBS. The slides 
were then placed into warm sodium citrate for antigen retrieval and microwaved 
on the low heat setting for 10 minutes. Slides were then cooled in sodium citrate 
for 20 minutes and then washed with 1x PBS once and twice with 1x PBS+0.3% 
TritonX-100 to permeabilize the cell membranes. Primary antibody diluted in 1x 
PBS+0.3% TritonX-100 +1% BSA was then added to slides. Slides were incubated 
overnight at 4°C. The slides were then washed with 1x PBS+0.3% TX-100 three 
times and incubated in secondary antibody diluted in 1x PBS+0.3% TritonX+1% 
BSA for 1 hour at room temperature in the dark. Slides were then washed with 1x 
PBS+0.3% TritonX-100 twice and counterstained with DAPI. After washing slides 
with 1x PBS+0.3% TritonX-100 twice and 1x PBS once, slides were mounted and 
imaged using one of three microscopes: Leica CTR 6500 microscope, ZEISS 
Axioscop40 microscope and Leica DM5500B microscope. Figure 6A is an example 
of a sagittal section and the areas of interest in this study. The hippocampus is 
imaged many times in this study and its components have been labeled in Figure 
6B. A list of primary and secondary antibodies used, and their respective dilutions, 
in this study are represented in Table 5. Blind cell counts were performed on many 
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of these slides for different experiments throughout this work. Volocity software 
was used to set the pixel/μm for each microscope and create a fixed area that 
remained the same for each image analyzed. This fixed area was placed on each 
image and cell counts were performed within its boundaries. 
2.6 Microarray Analysis  
A microarray was performed comparing Atrxf/YFoxG1-Cre+ (conditional knockout) 
and AtrxWT/YFoxG1-Cre- (control) males at P17 (unpublished, Michael Levy). Three 
P17 control and conditional knockout male forebrains were dissected and total 
RNA was extracted using the RNeasy Mini kit (Qiagen). cRNA was generated and 
hybridized to an Affymetrix Mouse Genome 430 2.0 Array at the London Regional 
genomics Center (London, Canada). One microarray chip per mouse was used 
and probe intensities were measured using GCOS1.4 (Affymetrix Inc.). Specific 
genes enriched in the astrocyte population were selected from this microarray 
based on a recently published study that generated a transcriptome database 
comparing 8 cell types in brain (Zhang et al., 2014). The top 48 genes that were 
enriched by more than 30 fold in astrocytes were selected and the intensity of RNA 
binding to each genetic probe was assessed. Heat maps indicating intensity of 
probe binding for each sample were generated using Partek software. Gene 
ontology (GO) analysis was performed on genes with altered expression. Gene 
levels were calculated using RMA pereprocessor in GeneSpring GX 7.3.1 (Agilent 
Technologies Inc.) and fold-change calculated using p<0.05.  
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Table 4. Primers used for qRT-PCR. 
Primer Name Sequence (5’ to 3’) 
Atrx 17F AGAACCGTTAGTGCAGGTTCA 
Atrx 18R TGAACCTGGGGACTTCTTTG 
Gapdh F CAACGACCCCTTCATTGACCT 
Gapdh R ATCCACGACCGACACATTGG 
Gjb6 F GCCCTGGAGAACAAGACTCA 
Gjb6 R CTCATCACCCCACACTTCCT 
Gja1 F GAGAGCCCGAACTCTCCTTT 
Gja1 R TGGAGTAGGCTTGGACCTTG 
Slc1a2 F AGATCATCGCCATCAAGGAC 
Slc1a2 R TCCAAGCAACGGAAGGTAAC 
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Table 5. List of antibodies used for immunofluorescence (IF) and western 
blot (WB) experiments 
Antibody Description and company Dilution used in IF and 
WB 
GFAP Mouse monoclonal antibody, 
Sigma  
IF: 1:100 
WB: 1:2000 
ATRX H-300 Rabbit polyclonal antibody, 
Santa Cruz 
IF: 1:100 
ALDH1L11 Mouse monoclonal antibody, 
Millipore 
IF: 1:50 
WB: 1:1000 
Secondary 
antibody - red 
Alexa Fluor 594 nm, goat anti-
rabbit IgG, Life Technologies 
IF: 1:800 
Secondary 
antibody - 
green 
Alexa Fluor 488 nm, goat anti-
mouse IgG, Life Technologies 
IF: 1:800 
Secondary 
antibody - HRP 
Rabbit anti-mouse IgG HRP, 
Santa Cruz 
WB: 1:4000 
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Figure 6. Regions of the mouse brain used for experimental analysis. (A) 
Image of a sagittal section of the mouse brain with the cortex, hippocampus and 
cerebellum. (B) Hippocampus enlarged and labelled for its 4 distinct regions: 
cornus ammonis 1 (CA1), 2 (CA2), 3 (CA3) and the dentate gyrus (DG). Images 
were adapted from the Allen Brain Atlas website, available online at 
www.brainmap.org. 
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3 Results  
3.1 Assessing the astrocyte population in Atrxf/YFoxg1-Cre 
mice 
The FoxG1 driven Cre recombinase is active in all cell types in the forebrain and 
expression begins at approximately E8.5 (Hebert and McConnell, 2000). Previous 
studies have demonstrated that loss of ATRX in the forebrain resulted in increased 
DNA damage induced by replication stress and reduced cortical mass due to 
increased p53-mediated cell death in neuroprogenitor cells (Berube et al., 2005; 
Ritchie et al., 2014; Seah et al., 2008; Watson et al., 2013). What occurs in the 
other cell types in the Atrx-null forebrain has not yet been elucidated. To examine 
the astrocyte population, samples collected by previous graduate students (Kieran 
Ritchie and Matt Edwards) from previously assessed timepoints (P7 and P20, 
respectively) using the FoxG1 conditional deletion of Atrx were analyzed. Coronal 
cryosections from P7 control and conditional knockouts (cKO) were stained with 
GFAP to determine astrocyte reactivity in an environment with neuronal cell death 
(Figure 7). There appears to be more reactive astrocyte activation in the cKO 
based on GFAP staining in outlined area (Figure 7). This result is not quantifiable 
and therefore a western blot assessing GFAP protein levels was performed next.   
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Figure 7. Potential reactive astrocyte activation in cKO hippocampus 
compared to control at P7. Coronal cryosections were immunostained with glial 
fibrillary acidic protein GFAP (green) and analysis of the hippocampus (outlined 
and labeled in white) revealed increased GFAP activation in the hippocampal 
space, outlined in yellow, in the cKO. n=2. Scale bar=205 μm.  DG=Dentate gyrus, 
CA1=Cornu Ammonis 1, CA2=Cornu Ammonis 2 and CA3= Cornu Ammonis 3. 
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To determine quantitative levels of GFAP protein levels, a Western blot was 
performed on P20 forebrain samples of three control and cKO pairs. ALDH1L1 
levels, a cytoplasmic marker that more broadly and specifically labels astrocytes 
throughout the brain (Cahoy et al., 2008), were also assessed. Western blot 
analysis of these two astrocyte markers revealed a decrease in ALDH1l1 protein 
levels in the cKO, however the difference was not significant (Figure 8A, B). GFAP 
protein levels were slightly increased, but not significantly, in the cKO compared 
to control (Figure 8A, B). Increased GFAP levels could indicate there are more 
reactive astrocytes present in the forebrain in the cKO. Decreased ALDH1L1 
protein levels could indicate decreased protein levels per astrocyte or a decrease 
in the amount of astrocytes present in the forebrain. GFAP levels were analyzed 
relative to ALDH1L1 levels (Figure 8C) to determine if GFAP levels are increased 
per astrocyte. There is no significant difference between control and cKO 
GFAP/ALDH1L1 protein levels. To determine if the nonsignificant decrease in 
ALDH1L1 could be due to a decrease in astrocyte number, cell counts were 
performed.  
Cell counts on P20 control and cKO coronal cryosections immunostained for 
ALDH1L1 and DAPI were performed where DAPI-stained nuclei surrounded by 
cytoplasmic ALDH1L1 staining were counted as an astrocyte. These counts were 
performed while blinded on three pairs of control and cKO cryosections, with 3 to 
4 sections per slide. The number of astrocytes per 100,000 μm2 for each section  
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Figure 8. Quantification of ALDH1L1 and GFAP proteins levels in the cKO 
forebrain at P20 (A) Protein extracts from control and cKO forebrain were isolated 
and ALDH1L1 and GFAP levels assessed via immunoblotting. (B) Quantification 
of protein levels revealed an insignificant decrease in ALDH1L1 in the cKO. GFAP 
levels remained unchanged. (C) GFAP levels were assessed relative to ALDH1L1 
expression, revealing a slight but insignificant increase in the cKO. ALDH1L1 and 
GFAP levels normalized to INCENP levels.  
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was averaged for each control and cKO. The control and cKO cell counts were 
then averaged and this revealed no significant difference in the number of Aldh1l1 
positive nuclei in cKO compared to control (Figure 9A). When assessing the 
individual pairs of control and cKO astrocyte cell counts, two pairs demonstrate a 
decrease in astrocyte number in the cKO, but one pair showed the opposite result 
(Figure 9B). This demonstrates a variability in the astrocyte population between 
pairs. Comparing immunofluorescence staining of Aldh1l1 between cKO and 
control mice in pair 2 revealed lower intensity of fluorescence in the cKO (Figure 
9C). This is paired with a decrease in the number of astrocytes counted in pair 2 
(Figure 9B).  These results indicated that the amount of astrocytes in the cKO is 
variable between cKO males. GFAP levels may be increased relative to the 
number of astrocytes present in the cKO (Figure 8C), but this phenotype was also 
variable between cKO males (Figure 8A). Overall, we conclude that this cKO 
mouse model is not ideal for studying the effect of ATRX loss in astrocytes due to 
the non-cell-autonomous effects from ATRX deletion in other cell types, which may 
underlie the high variability observed between samples. 
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Figure 9. The number of astrocytes is not changed in the cortex of P20 cKO 
males compared to controls. (A) Cell counts were performed on P20 coronal 
cryosections of control and cKO cortex stained for ALDH1L1 and DAPI. Cell counts 
on 3 to 4 brain sections for each control and cKO mouse were performed and 
averaged per 100,000 μm2. (B) Cell counts of each pair of control and cKO is 
shown here to demonstrate variability between pairs from different litters. (C) 
Example of immunofluorescence staining for pair 2 (C2 and cKO2) where Aldh1l1 
staining (green) surrounds DAPI stained nuclei (blue). Outlined areas of the cortex 
are enlarged and arrowheads indicate examples of astrocytes (ALDH1L1+ nuclei). 
n=3. Scale bar=100 μm. 
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To further examine the effects of Atrx inactivation in astrocytes, astrocyte-enriched 
genes were analyzed in a previously performed microarray comparing 3 control 
and 3 cKO males at P17 (unpublished, Michael Levy). To determine which genes 
were enriched in astrocytes a recently published RNA transcriptome comparing 
oligodendrocytes, neurons, microglia, astrocytes and vascular cells in the mouse 
cerebral cortex was used (Zhang et al., 2014). The top 48 genes that were enriched 
more than 30-fold in astrocytes, compared to all other central nervous system cell 
types, were examined in the microarray (Figure 10A). Heat maps displaying the 
intensity of RNA-binding to each gene probe were generated, comparing 3 control 
and cKO males (Figure 10A). Aqp4, an astrocyte-specific water channel, displayed 
the most changed binding-intensity and is down-regulated (2-fold) in the cKO 
(Figure 10A). Deiodonase-2 (Dio2), the enzyme responsible for thyroid hormone 
activation was also displays lower binding intensity in the cKO and is significantly 
downregulated (1.6-fold), along with Tenasin C (Tnc) (1.6-fold), an extracellular 
matrix protein gene that is implicated in guidance of migrating neurons and axons 
during development and synaptic plasticity. Slc4a4, the 4th most down-regulated 
gene in the cKO (1.4-fold), is a protein important for glucose transport and 
maintaining intracellular pH. GO analysis was performed on these astrocyte-
enriched genes and the top 10 altered gene groups based on biological function 
are shown in Figure 10B. One-carbon compound transport genes, such as those 
important for carbon dioxide and urea transport, were the most altered in the list of  
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Figure 10. Astrocyte-enriched genes demonstrate altered transcript levels in 
the forebrain of cKO males at P17. (A) Heat map representing the RNA-binding 
intensity of the top 48 astrocyte-enriched genes in a microarray performed on 3 
control and 3 cKO mice. Genes listed are from most down-regulated in cKO to 
most upregulated, based on RNA-binding intensity. (B) Gene ontology (GO) for 
astrocyte-enriched genes reveals altered functional pathways in astrocytes. Heat 
map generation and GO analysis were performed using Partek software, p<0.05, 
C=control, K=conditional knockout. 
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astrocyte- enriched gene list (Figure 10B). Urea and amide transport genes were 
also enriched in altered genes, as well as water transport and membrane 
component genes (Figure 10B). The membrane component genes altered in the 
GO analysis overlap with many transporter genes altered in the microarray that 
reside in the membranes of astrocytes. Conditional deletion of Atrx by Cre 
recombinase driven by the FoxG1 promoter results in complete deletion in the 
forebrain and therefore makes the effects of Atrx loss in one cell type, such as 
astrocytes, difficult to detect. To eliminate any cell non-autonomous effects from 
other cell types, a model that deletes Atrx specifically in astrocytes is required. 
3.2 Creation of a novel mouse model deleting Atrx in 
astrocytes  
To study the role of ATRX in astrocytes specifically, a new mouse model was 
required.  Atrxf/WT females were crossed with Glast-CreERT males to generate 
inducible KO (Atrxf/YGlast-CreERT) and control (AtrxWT/YGlast-CreERT) males. Cre 
recombinase under the Glast promoter will delete Atrx in astrocytes specifically. 
Tamoxifen administration results in Cre recombinase translocation to the nucleus 
and recombination at any loxP sites present in the genome. To validate that 
tamoxifen successfully induces deletion of Atrx expression in astrocytes, 
preliminary tamoxifen injections were performed on 3 month old inducible knockout 
and control males. One week post-final injection, male mice were sacrificed and 
hippocampal tissue was harvested for mRNA isolation. qRT-PCR of Atrx 
demonstrated no detectable change in Atrx expression (Figure 11A).  P10, the  
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Figure 11. Atrx expression is not significantly decreased in the hippocampus 
of inducible knockout males. (A) Control and inducible knockout male mice were 
injected at 3 months of age for 5 consecutive days with 2 mg of tamoxifen. One 
week post-final injection, hippocampal RNA was isolated and mRNA levels of Atrx 
are not significantly decreased (p= 0.171) (B) Control and inducible knockout 
males were injected at P10 for 3 consecutive days with 1 mg of tamoxifen. Two 
weeks post-final injection, hippocampal RNA was isolated and no detectable 
change between control and inducible KO was observed (p= 0.743). Relative 
expression of Atrx was normalized to Gapdh. n=3. 
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Figure 12. Atrx expression in the cortex of P26 contorl and inducible KO 
mice. (A) P26 cortical Atrx expression revealed no significant difference between 
3 control and inducible KO pairs (p=0.0584). (B) Individual control and inducible 
KO pairs demonstrated variability in inducible KO Atrx expression after tamoxifen 
administration. Relative expression normalized to Gapdh expression. n=3. 
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injection start timepoint used throughout the rest of this work, control and inducible 
KO males were injected with tamoxifen for 3 consecutive days and sacrificed 2 
weeks post-final injection at P26. Analysis of Atrx mRNA expression in the 
hippocampus of inducible KO revealed no detectable change from control levels 
(Figure 11B). Atrx mRNA levels were also measured in the cortex at P26 after P10 
to P12 injection with tamoxifen. Although overall there is no significant change in 
average Atrx expression in the cortex of three pairs of control and inducible KO 
males (Figure 12A), if each pair is analyzed individually, there is variation in Atrx 
expression between pairs from different litters (Figure 12B). Pair 1 demonstrated 
decreased Atrx expression, however pair 2 displayed no change and pair 3 
indicated a smaller decrease than pair 1 (Figure 12B). This variability between 
pairs contributed to no significant change being observed overall (Figure 12A). 
Overall, because Atrx is deleted in a subset of astrocytes and is still expressed in 
other cell types in the brain, detecting changes in Atrx by qRT-PCR is difficult. The 
expression of Atrx in neurons, oligodendrocytes and other cell types may be 
clouding any decrease in Atrx expression in astrocytes. Therefore, a different 
method, such as assessing whether ATRX is present in cells by 
immunofluorescence detection is required. 
To validate that Atrx is being deleted specifically in astrocytes, cell counts were 
performed in a blinded manner on P26 control and inducible KO sagittal 
cryosections 2 weeks post-tamoxifen injection (Figure 13A). The sections were 
immunostained for GFAP, ATRX and DAPI. Three control and inducible KO males,   
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Figure 13. Percent of GFAP+ nuclei lacking ATRX is significantly increased 
in P26 hippocampus of inducible knockout compared to control. (A) Sagittal 
sections of control and inducible knockout hippocampi stained for GFAP (green), 
ATRX (red) and DAPI (blue). (B) Enlarged area of the hippocampus from (A). 
Arrowheads indicate GFAP positive cells expressing ATRX and full arrows indicate 
GFAP positive cells without ATRX staining. (C) Quantification of percent of GFAP 
positive nuclei that do not express ATRX. * indicates p<0.05, n=3. Scale bar=100 
μm 
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with one slide containing 3 sections for each of the 6 mice, were assessed. GFAP 
positive nuclei were counted, regardless of ATRX staining. Next, the GFAP 
positive but ATRX negative nuclei were counted in the same area. The number of 
GFAP positive nuclei lacking ATRX staining present in the hippocampus of 
inducible KO males was significantly higher when compared to controls (Figure 
13C). An average of 34.4% of GFAP positive nuclei did not contain ATRX staining. 
Although ATRX is deleted in many GFAP-positive astrocytes (indicated by full 
arrows in Figure 13B), it is not deleted in all astrocytes, as indicated by arrowheads 
in Figure 13B. ATRX may be deleted in another astrocytes that do not express 
GFAP and therefore the deletion of ATRX in astrocytes may be more widespread 
than reported by GFAP and ATRX co-staining alone. Glast-CreERT is also 
expressed in Bergmann glia in the cerebellum, and therefore ATRX staining in the 
cerebellum was also assessed.  Immunostaining for GFAP, ATRX and DAPI was 
performed in the cerebellum of one P26 control and one inducible KO male. Many 
DAPI positive nuclei lacking ATRX staining were present in the inducible KO, 
where all nuclei in the control exhibited ATRX staining (Figure 14).  Some of the 
ATRX-null nuclei are not surrounded by GFAP staining. These cells would require 
staining with another astrocyte marker to demonstrate they are indeed astrocytes. 
It is likely these nuclei lacking GFAP cytoplasmic staining are a different subtype 
of astrocyte expressing lower levels of GFAP. Overall, the ATRX staining in the 
cerebellum indicates that the Glast-CreERT allows for Cre activation and  
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Figure 14. ATRX protein expression is decreased in cerebellum of P26 
cerebellum of inducible KO. Sagittal sections of control and inducible KO 
hippocampi stained with GFAP (green), ATRX (red) and DAPI (blue) revealed 
DAPI positive nuclei lacking ATRX staining, as indicated by arrowheads. n=1. 
Scale bar=25 μm. 
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recombination after tamoxifen administration.  
GFAP does not label all astrocytes in the brain (Cahoy et al., 2008), and this makes 
visualization of Atrx deletion in astrocytes by immunofluorescence staining difficult. 
Therefore one copy of a double fluorescent reporter allele, mT/mGWT/+, was 
crossed into the Atrxf/WT female mice. The female mice carrying the double 
fluorescent reporter allele were crossed with Glast-CreERT male mice to produce 
fluorescent control (AtrxWT/YGlast-CreERT mT/mGWT/+) and fluorescent inducible 
knockout (Atrxf/YGlast-CreERT mT/mGWT/+). The male mice will express GFP in 
astrocytes after Cre recombinase activation by tamoxifen. To ensure that GFP 
expression is specific to Cre recombinase activation by tamoxifen, male mice with 
and without the Glast-CreERT but carrying a copy of the double fluorescent reporter 
allele (AtrxWT/YmT/mGWT/+ and Atrxf/YGlast-CreERT mT/mGWT/+, repectively) were 
injected from P10 to P12 and sacrificed 2 weeks post-final injection (at P26). One 
of these males (AtrxWT/YmT/mGWT/+) does not contain Cre recombinase and 
therefore tamoxifen administration will not induce recombination and subsequent 
GFP expression from the double fluorescent reporter allele.  The brains were 
sectioned sagitally and stained with DAPI to identify nuclei. The male lacking the 
Glast-CreERT allele and carrying the mT/mG allele demonstrated no GFP 
expression after exposure to tamoxifen in both the cortex (Figure 15A) and 
hippocampus (Figure 15B). The male carrying the double reporter allele and the 
Glast-CreERT allele demonstrated successful GFP induction (Figure 15A, B), 
indicating that tamoxifen administration is activating Cre recombinase activity. 
  
66 
 
 
 
Figure 15. GFP expression in the cortex and hippocampus after tamoxifen 
administration in male mice carrying the mT/mG allele. (A) Sagittal sections of 
the cortex from males possessing both the mT/mG allele and with (right) or without 
(left) the Glast-CreERT allele were stained with DAPI to reveal cytoplasmic GFP 
induction after tamoxifen administration only in the presence of the Glast-CreERT 
allele. (B) Sagittal sections of the hippocampus from males possessing the mT/mG 
allele and with (right) or without (left) the Glast-CreERT allele were stained with 
DAPI to reveal cytoplasmic GFP induction after tamoxifen administration only in 
the presence of the Glast-CreERT allele. Scale bar=360 μm. 
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3.3 Preliminary morphological assessment of ATRX-null 
astrocytes 
Astrocyte morphology can reflect astrocyte function. The cytoplasmic expression 
of GFP from the recombined mT/mG double reporter allele therefore provides an 
ideal system for studying morphology in astrocytes lacking Atrx. Astrocyte 
morphology was assessed after tamoxifen administration of control and inducible 
KO littermate pairs harbouring the mT/mG allele (Figure 5). Fluorescent control, 
AtrxWT/YGlast-CreERTmT/mGWT/+, and fluorescent inducible KO, Atrxf/YGlast-
CreERTmT/mGWT/+, P26 sagittal cryosections were stained with DAPI and 
compared for GFP expression (Figure 16). The hippocampus of the fluorescent 
inducible KO demonstrated an increase in GFP domain number, however the 
astrocyte domain size appeared to be similar between fluorescent control and 
fluorescent inducible KO. Glast-CreERT is also expressed in neural stem cell 
present in the dentate gyrus (Mori et al., 2006; Slezak et al., 2007), which is 
outlined in Figure 16A. GFP expression in this region was different when compared 
to the staining of hippocampal astrocytes (Figure 16A).  
A striking increase in GFP domains in the cortex was demonstrated in fluorescent 
inducible KO compared to fluorescent control in the cortex (Figure 16B), indicating 
Cre recombinase expression is induced in more astrocytes. Astrocytic domains, 
visualized by GFP expression, also appeared larger in the fluorescent inducible 
KO, indicating larger astrocyte domains or more overlap between individual 
astrocyte domains (Figure 16C).  
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Morphological maturation is connected to molecular maturation and therefore 
expression of astrocyte maturation genes in the inducible KO should be assessed.  
To determine if loss of ATRX in astrocytes has an effect on astroglial maturation 
genes, qRT-PCR was performed on P26 (2 weeks post-injection) control and 
inducible knockout cortex. Relative expression of connexin 30 (Gjb6), connexin 43 
(Gja1) and glutamate transporter Glt1 (Slc1a2) revealed no significant change 
between control and inducible KO (Figure 17). However, Connexin 30 expression 
did appear decreased without reaching statistical significance. Increasing the 
number of biological replicates and assessing protein levels of connexin 30 will be 
required to clarify this result. 
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Figure 16. ATRX- GFP+ astrocytes display altered morphology in the P26 
cortex. (A) GFP expression was induced in the hippocampus of fluorescent 
control (AtrxWT/YmT/mGWT/+ GlastCreERT) and fluorescent inducible KO 
(Atrxf/YmT/mGWT/+ GlastCreERT). Expression of GFP was also in neural stem cells 
in outlined dentate gyrus. Scale bar= 500 μm (B) GFP was expressed in more 
astrocytes, giving rise to more GFP positive domains, in the inducible KO cortex. 
Domains also appear larger in fluorescent inducible KO compared to fluorescent 
control. Scale bar= 200 μm. (C) Higher magnification of GFP domains revealed 
larger domains with higher intensity of GFP expression in fluorescent inducible 
KO. Scale bar= 100 μm. 
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Figure 17. Expression analysis of astroglial genes in the P26 cortex of 
control and inducible KO mice. Analysis of control and inducible KO cortical 
transcript levels at 2 weeks post-injection (P26) revealed no significant change in 
connexin 30 (Gjb6) (p=0.101), connexin 43 (Gja1) (p=0.287) and Glt1 (Slc1a2) 
(p=0.876). Relative expression normalized to Gapdh expression. n=3.   
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4 Discussion  
4.1 Loss of ATRX in the forebrain affects the astrocyte 
population 
4.1.1 Aldh1l1 expression and the number of astrocytes present in 
the cKO is variable  
The deletion of Atrx beginning at E8.5 in the forebrain by Cre recombinase driven 
by the Foxg1 promoter resulted in p53-mediated apoptosis of neuroprogenitors 
and microcephaly in the mouse brain (Berube et al., 2005; Ritchie et al., 2014; 
Seah et al., 2008). It is well established that ATRX is required for maintenance of 
the neuroprogenitor pool and its loss causes sensitivity to replicative stress (Ritchie 
et al., 2014; Watson et al., 2013). However, the effects on the astrocyte population 
remain unclear.  The increased amount of neuroprogenitor cell death in the 
embryonic brain of the cKO indicates that astrocytes may respond by becoming 
reactive (Sofroniew and Vinters, 2010). Astrocytes are not generated until after 
birth (Yang et al., 2013), however the cell death observed in the neuroprogenitor 
population occurs embryonically (Berube et al., 2005; Seah et al., 2008; Watson 
et al., 2013). Reactive astrocytes may remain reactive to block off damage in the 
brain (Sofroniew and Vinters, 2010). Assessment of immunofluorescent staining 
for GFAP in the hippocampus revealed an increase in 2 pairs of P7 control and 
cKO coronal sections (Figure 7). It is possible that GFAP staining would be higher 
closer to birth, after the first astrocytes are born and begin to react to their 
environment.  
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Quantitative analysis of GFAP by western blot revealed no significant change in 
the expression of this astrocyte-specific marker (Figure 8A, B). However, the 
possibility of whether there was a decrease in the number of astrocytes in the cKO 
needed to be addressed. Although the protein levels of Aldh1l1, a more global 
astrocyte-specific marker (Cahoy et al., 2008), did not show significant change 
between control and cKO when averaged between three pairs, variability was 
observed in the western blot (Figure 8A). Pairs 1 and 2 showed a decrease in the 
expression of Aldh1l1 in cKOs compared to controls, but pair 3 did not show the 
same trend (Figure 8A). To determine whether this decrease in Aldh1l1 was due 
to decreased protein expression per cell or a decrease in the astrocyte population 
overall (Figure 9A), cell counts of Aldh1l1 positive cells in the cortex of three control 
and cKO pairs were performed and also revealed inconsistencies between pairs 
(Figure 9B): two pairs demonstrated a decrease in astrocytes number in the cKO 
and one pair displayed the opposite result. Immunostaining also revealed 
decreased intensity of Aldh1l1 staining in the cKO, indicating there may be 
decreased levels of Aldh1l1 per astrocyte (Figure 9C). The biological variability in 
these experiments is likely a result ATRX loss in these cells. If there were less 
astrocytes in the cKO forebrain, GFAP levels may be increased per astrocyte as 
there was an increase (nonsignificant) in the cKO males (Figure 8B). Indeed, when 
GFAP protein levels were normalized to Aldh1l1, GFAP levels were increased, 
however this increase was still not statistically significant (Figure 8C). Analysis of 
additional mice might help to determine if astrocyte number is consistently 
decreased and if there is a higher number of reactive astrocytes in the cKO. This 
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could result in altered astrocyte function in the cKO brain as reactive astrocytes 
alter their gene expression to contain damage and inflammation, thereby 
neglecting normal functions (Zamanian et al., 2012). These results are, however, 
variable between control and cKO pairs. A better model to study ATRX inactivation 
in astrocytes, without cell non-autonomous effects, was required and is discussed 
further in section 4.2. 
4.1.2 ATRX loss in the embryonic forebrain results in altered 
expression of astrocytes enriched genes. 
A microarray assessing altered gene expression in control and cKO was previously 
performed in our lab (unpublished, Michael Levy). The analysis of microarray data 
at P17 indicated that many astrocyte-enriched genes exhibited altered expression, 
based on microarray binding intensities, in the ATRX-null forebrain. (Figure 10A). 
The top 3 downregulated genes were all decreased by approximately 1.6 to 2-fold.  
Aqp4 was the most altered astrocyte-enriched gene and was downregulated 2-fold 
in the cKO forebrain. AQP4 channels are present at the endfeet of astrocytes and 
make contacts with the blood brain barrier and the barriers of cerebral spinal fluid 
vessels (Amiry-Moghaddam and Ottersen, 2003; Gomes et al., 2009). They also 
colocalize with potassium channel Kir4.1 at the membrane of astrocytic endfeet 
and PAPs, assisting with potassium transport by concentration gradient regulation 
in the brain (Amiry-Moghaddam and Ottersen, 2003; Gomes et al., 2009). Deletion 
of Aqp4 in glia resulted in reduced water absorption at the blood-brain barrier, but 
did not increase permeability to macromolecules (Haj-Yasein et al., 2011). AQP4 
is important in regulating the extracellular space of synapses during excitatory 
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synaptic transmission in the brain (Haj-Yasein et al., 2012). This decrease in Aqp4 
could affect synaptic function in the cKO brain and overall water and potassium 
homeostasis.  
Dio2 was the second most downregulated gene in the cKO P17 forebrain. DIO2 is 
the enzyme responsible for converting thyroxine (T4) into the active thyroid 
hormone triiodothyronine (T3) and its expression takes place predominantly in glial 
cells, specifically in astrocytes (Morte and Bernal, 2014). Astrocytes can take up 
circulating T4 from the blood through their connections with the blood brain barrier 
and T4 can be converted to T3 through DIO2-mediated deiodination (Morte and 
Bernal, 2014). This decrease in Dio2 could lead to decreased T3 production in the 
brain. T3 is important for brain development and has been linked to neuronal 
migration, synaptogenesis and myelination (Preau et al., 2015). Interestingly, cKO 
have decreased serum T4 levels (Watson et al., 2013) and also exhibit decreased 
levels of myelin proteins at P20 (Matthew Edwards, unpublished). Given that 
astrocytes are responsible for converting T4 to T3 through DIO2, they may play a 
role in the myelination defects observed in cKO males. 
Tnc was downregulated to a similar degree as Dio2. TNC is an astrocyte-secreted 
molecule that is involved in extracellular matrix remodeling after brain injury and in 
synaptic plasticity and axonal guidance during brain development (Jones and 
Bouvier, 2014). TNC can promote or inhibit synapse formation during 
development, depending on other signals present (Jones and Bouvier, 2014). 
TNC-null mice exhibited high neuronal density, increased reactive astrogliosis, and 
reduced LTP in the hippocampus (Evers et al., 2002; Irintchev et al., 2005). Tnc 
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expression decreases in the adult brain after development but an increase in its 
expression is correlated with the induction of reactive astrocytes (Jones and 
Bouvier, 2014). In fact, GFAP levels were significantly lower in TNC-null reactive 
astrocytes when compared to wildtype and inflammatory cytokine levels were also 
altered (Ikeshima-Kataoka et al., 2008). Therefore, if Tnc is downregulated in the 
cKO, this could impact synaptogenesis as well as how astrocytes respond to injury 
or inflammation. This decrease in Tnc expression could also result in GFAP not 
being upregulated to its full extent in reactive astrocytes, yielding an insignificant 
change in protein levels observed in Figure 8.  
GO analysis identified enriched pathways in altered genes. The majority of altered 
pathways involved homeostatic functions, such as urea transport and water 
transport performed by astrocytes (Figure 10B). Integral and intrinsic membrane 
components were also enriched in altered genes and this refers to the many 
transporters and channels present on the membrane of astrocytes that are altered 
in the cKO. Taken together, the results suggest homeostatic functions of 
astrocytes are altered in the cKO, contributing to pathology in the brain.  
4.2 Creation of a novel mouse model 
To further study the role of ATRX in astrocytes, Cre recombinase driven by an 
astrocyte-specific promoter was required to delete Atrx. To accomplish this, a 
cross between Atrxf/WT females and males carrying the Glast-CreERT allele was 
performed. This Cre recombinase is activated by tamoxifen administration, 
causing recombination of the floxed Atrx allele in astrocytes. This model also 
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allows for temporal control of Atrx deletion in astrocytes. Efficient recombination of 
the floxed Atrx gene was difficult to detect as qRT-PCR analysis of Atrx expression 
in the hippocampus could not detect a significant decrease in the inducible KO at 
3 months of age (Figure 11A). This difficulty can be explained by all other cell types 
still expressing Atrx in the inducible KO and the small change in astrocyte-specific 
Atrx expression is undetectable as a result of the high expression of the gene in 
other cell types. A more effective approach will be to use a fluorescent reporter 
allele that is activated by Glast-CreERT to purify control and inducible KO astrocytes 
with fluorescence-activated cell sorting (FACs). This will provide a relatively pure 
astrocyte populations and deletion of Atrx would be detectable in males carrying 
the floxed Atrx allele. 
Previous studies identified ATRX as important for neuroprogenitor survival when 
ATRX was deleted embryonically (Berube et al., 2005; Ritchie et al., 2014; Seah 
et al., 2008; Watson et al., 2013). Given the importance of ATRX in proliferating 
cells, injection during peak astrogliogenesis was avoided as to not induce 
replication, DNA damage, and apoptosis in astrocytes. Instead, control and 
inducible KO males began injections at P10, and ended at P12, as peak 
astrogliogenesis ends at approximately P7 (Yang et al., 2013). Atrx mRNA levels 
were not significantly decreased in the hippocampus (Figure 11B). Tamoxifen 
injections may cause variability in Cre recombinase induction if one male receives 
less tamoxifen than another due to human error. Also, the brain is smaller at P26 
as it is developing and hippocampal dissection is difficult. It is possible that the 
high expression of Atrx in neurons may shield any decrease in astrocytes from 
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being observed. More tamoxifen treated control and inducible KO pairs must be 
assessed to determine if there is a detectable. qRT-PCR performed on P26 control 
and inducible cortex also demonstrated no significant change in average 
expression in three pairs (Figure 12A). If each pair is analyzed individually, 
however, it is clear that there is variability in Atrx expression (Figure 12B). Pair 1 
exhibited a significant decrease in Atrx levels by approximately 50% and Pair 3 
also showed a decrease in inducible KO, however not to the same extent. Pair 2 
demonstrated no change in Atrx levels between control and inducible KO. This 
variability could be due to different tamoxifen levels reaching the brain after 
injection. To determine whether this decrease in the cortex is consistent, more 
biological replicates must be performed to rule out any technical issues with 
tamoxifen delivery via intraperitoneal injection. Also a FACs experiment, as 
mentioned in the above paragraph, could be used to isolate the astrocyte 
population and assess the deletion of Atrx at this timepoint. 
The protein levels of ATRX in astrocytes revealed that an average of 34.4% of 
GFAP positive nuclei lacked ATRX staining in a selected area of the hippocampus 
(Figure 13C). It is important to note that GFAP does not stain all astrocytes (Figure 
13A, B) and therefore this may underestimate the recombination efficiency. 
Immunostaining in the cerebellum also revealed nuclei lacking ATRX staining, 
some surrounded by cytoplasmic GFAP staining and some not (Figure 14). These 
ATRX-deficient nuclei lacking GFAP staining could indicate that another subtype 
of astrocyte, which does not express GFAP at detectable levels, expressed Cre 
recombinase in response to tamoxifen. One major challenge in the field is a lack 
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of a nuclear astrocyte marker, and the heterogeneity of astrocytes makes 
cytoplasmic marker ALDH1L1 the best candidate for labeling the most astrocytes 
(Cahoy et al., 2008).  Cell counts in the cortex after tamoxifen injection should 
therefore be performed using an anti-Aldh1l1 antibody. This will allow for validation 
of ATRX deletion at the protein level in the cortex. A double reporter allele, 
however, was used to track Cre recombinase induction after tamoxifen injection. 
This allele expressed GFP after Cre recombinase-mediated recombination, and 
therefore after tamoxifen treatment in astrocytes in this model. Figure 15 
demonstrates that GFP expression is only observed in the presence of the Glast-
CreERT allele, indicating that tamoxifen is reaching the brain and inducing 
recombination. This also shows that tamoxifen can cross the blood brain barrier 
successfully and bind the estrogen receptor-fused Cre recombinase, allowing for 
its translocation to the nucleus.  
4.3 Altered morphology and decreased expression of gap 
junction protein in inducible KO 
4.3.1 Increase in number of astrocytes undergoing recombination 
and altered morphology in the cortex at P26 in inducible KO 
Through use of a double reporter allele, astrocyte domains and morphology were 
assessed in AtrxWT/YGlast-CreERTmT/mGWT/+ and Atrxf/YGlast-CreERTmT/mGWT/+ 
mice. Interestingly, in both the hippocampus and cortex of the fluorescent inducible 
KO there was an increase in the number of GFP domains (Figure 16A), which 
represent astrocyte domains as the GFP in the double reporter allele is membrane 
targeted (Muzumdar et al., 2007). The increase in GFP positive domains indicates 
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more astrocytes being exposed to tamoxifen at the blood brain barrier. It is 
important to note that before tamoxifen injection, the fluorescent control and 
inducible KO have the same gene expression as Atrx will not be deleted in 
astrocytes until after tamoxifen exposure. The injection protocol for these mice was 
3 consecutive, daily injections from P10 to P12 (Figure 11B). After the first 
injection, the permeability of astrocytes lacking Atrx to tamoxifen at the blood brain 
barrier may increase, leading to more astrocytes taking up tamoxifen from the 
blood in the daily injections that follow. Investigation as to why more astrocytes 
carrying the Atrx-floxed allele undergo recombination after tamoxifen 
administration is required to understand the mechanism of how ATRX loss may 
affect permeability of astrocytes to tamoxifen.  
In the cortex, the fluorescent inducible KO exhibited larger GFP positive domains 
(Figure 16B, C). This could indicate that 1) astrocyte morphology is altered such 
that individual astrocyte domains are larger in the inducible KO, 2) there is more 
overlap between individual astrocyte domains, or 3) a combination of the two. 
Because the GFP expressed form the double reporter allele is membrane targeted, 
it is difficult to distinguish if the large GFP domain is from one or multiple nuclei. 
Therefore if the large domains result from astrocytes having expanded PAPs, this 
could indicate a defect in morphological maturation. Astrocytes lacking ATRX do 
not respond to development cues that result in the pruning of their PAPs by 4 
weeks of age (Yang et al., 2013). This is also a possibility if the large GFP positive 
domains are caused by an overlap of multiple astrocytes. Astrocytes should retreat 
to non-overlapping domains by P28 (Yang et al., 2013). The timepoint analyzed 
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was P26 and therefore most astrocytes should occupy their own respective 
domains. The apparent domain expansion might be caused by a combination of 
increased astrocyte domain coverage and overlap between astrocytes. This 
morphology defect could be caused by delay in astrocyte morphological maturation 
due to ATRX loss or the permanent inability for ATRX-null astrocyte to prune their 
excess PAPs. To assess if this phenotype is permanent or a delay in development, 
the mutant mice should be assessed a month post-tamoxifen injection. If the 
phenotype persists, one could conclude that ATRX-null astrocytes have lost their 
ability to occupy specific domains.  
Regardless of whether this phenotype is a delay in maturation or a permanent 
increase in astrocyte domain size, it is clear that there are implications for 
synaptogenesis and synaptic plasticity. The timing of synaptogenesis overlaps 
with astrocyte morphological maturation (Figure 2). Astrocytes release factors that 
help with the pruning of unnecessary synapses during development (Bialas and 
Stevens, 2013). If astrocytes have enlarged domains, it is likely that they are 
making more connections with synapses. This could lead to decreased synaptic 
pruning if astrocytes themselves are not pruning PAPs during development. 
Assessment of TNF-β levels, the signal secreted from astrocytes to initiate 
synaptic refinement, should be assessed in the future. Dendrite morphology of 
neurons through Golgi staining would also provide insight as to whether synaptic 
refinement has taken place in the cortex of the inducible KO.  
If this phenotype is permanent, it has implications for synaptic plasticity in memory 
and learning after development. Astrocytes can help strengthen synapses during 
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a learning event by adjusting PAPs to contact synapses undergoing stimulation 
(Bernardinelli et al., 2014). The mobility of astrocytic PAPs is important to allow for 
selective contacts with synapses (Bernardinelli et al., 2014). If astrocytes cannot 
prune excess PAPs during development, they may also be unable to undergo PAP 
plasticity to reach and strengthen stimulated synapses in the adult brain. Further 
investigation is required to understand if astrocytes lacking ATRX retain structural 
plasticity, and more importantly if the enlarged astrocyte domains remain at later 
timepoints. Confocal microscopy and a primary antibody labeling GFP would 
enable better visualization of fine PAPs. 
4.3.2 Change in connexin 30 (Gjb6) expression in cortex of 
inducible KO at P26 
A nonsignificant decrease in connexin 30 (Gjb6) expression was observed at P26 
in the cortex of the inducible KO when compared to control (Figure 17). This 
decrease will need to be verified in a pure astrocyte population after using FACs 
to sort out control and inducible KO astrocytes. Western blot analysis of GJB6 
protein levels between control and inducible KO should be performed to determine 
if there is a significant decrease in the gap junction protein. If there is indeed a 
decrease in GJB6, there are many implications to astrocyte morphology and 
function.   GJB6 and GJA1 make up gap junctions present in astrocytes and allow 
for intercellular communications between astrocytes (Pannasch and Rouach, 
2013). These connections allow for efficient mediation of brain homeostasis 
through ion buffering and nutrient transport (Pannasch and Rouach, 2013). GJB6 
controls excitatory synaptic transmission in the hippocampus and does so by 
83 
 
mediating morphological changes that insert the astrocytic PAPs into synaptic 
clefts where glutamate transport can be more finely regulated (Pannasch et al., 
2014). GJB6-null mice have larger astrocytic domain with elongated processes 
and increased branching (Pannasch et al., 2014), a phenotype similar to the 
morphological changes observed in the fluorescent inducible KO. Loss of Gjb6 
also resulted in increased insertion of PAPs into synaptic clefts and altered 
excitatory transmission at the synapse (Pannasch et al., 2014). Therefore the 
decrease in Gjb6 expression in our mouse model could play a role in the 
morphological changes observed in ATRX-deficient astrocytes.  
Conclusions and future directions 
This study was initiated to address the potential functions of ATRX in astrocytes. 
We found that deletion of ATRX in all cells in the forebrain affected the astrocyte 
population by increasing the amount of reactive astrocytes. The results, however, 
were variable and firm conclusions could not be made. ATRX loss likely affects the 
number of astrocytes in the brain, as well as increasing their reactivity. More 
biological replicates are required to establish the consistency of these phenotypes. 
Analysis of microarray expression between control and cKO revealed ATRX 
deletion affects the expression of astrocyte-specific genes and pathways.  
A novel mouse model was created utilizing an inducible Cre recombinase under 
the control of an astrocyte-specific promoter. This Cre recombinase responds to 
tamoxifen administration, causing recombination of the floxed Atrx allele 
specifically and temporally in astrocytes. The use of a double reporter allele 
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revealed enlarged and possibly overlapping astrocyte domains in ATRX mutant 
mice compared to controls. This morphological change was accompanied by a 
potential decrease in expression of Cxn30, a key component of astrocyte gap 
junctions. Further analysis of connexin 30 expression at both the mRNA and 
protein level is required to determine if deletion of Atrx results in its decreased 
expression. 
The extent of ATRX inactivation on gene expression in astrocytes must be 
investigated further to understand the phenotypes observed above. Future 
directions for this study include assessing gene expression changes in ATRX-null 
astrocytes. Fluorescence-activated cell sorting could be used to isolate astrocytes 
and subsequent RNA sequencing would reveal changes between control and 
inducible KO. This would provide more insight into defects caused by ATRX loss 
in astrocytes. Another important question to answer involves whether ATRX-null 
astrocytes can support the growth and development of neurons, which could be 
addressed in co-culture experiments. Behavioural analysis of inducible KO mice 
would indicate whether ATRX is required in astrocytes for proper learning and 
memory. These experiments will indicate as to whether ATRX loss in astrocytes is 
contributing to the pathology experienced in the brains of individuals with ATR-X 
syndrome.  
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